Clinical Applications of Intravenous Immunoglobulins in Child Neurology

Title:Clinical Applications of Intravenous Immunoglobulins in Child Neurology

Volume: 18 Issue: 8

Author(s): Maria Gogou, Efimia Papadopoulou-Alataki, Martha Spilioti, Sofia Alataki and Athanasios Evangeliou*

Affiliation:

• 4th Department of Pediatrics, Papageοrgiou General Hospital, N. Efkarpia 56403, Thessaloniki,Greece

Keywords: Child neurology, children, encephalitis, epilepsy, immunotherapy, intravenous immunoglobulins.

Abstract: Background: While there are guidelines for the use of intravenous immunoglobulins in children with Guillain-Barre syndrome and myasthenia gravis based on high-level evidence studies, data are scarce for the majority of neurologic disorders in this age group. Neuronal antibodies are detected in children with seizures of autoimmune etiology. Intravenous immunoglobulins with their broad immunomodulatory mechanism of action could be ideally effective in different forms of immunedysregulated intractable epilepsies such as autoimmune epilepsy and autoimmune Rasmussen encephalitis. We conducted a systematic review of the literature for evidence of the use of intravenous immunoglobulins in a variety of neurologic diseases in childhood.

Method: A comprehensive literature search was conducted using Pubmed as the medical database source without date range. Prospective studies in pediatric groups including objective measures of clinical outcomes were systematically selected.

Results: A total of 11 prospective studies were identified in the literature demonstrating a favorable effect of this therapeutic option in children with drug-resistant epilepsy and in cases of encephalitis. No serious adverse effects were reported. No prospective studies about the use of intravenous immunoglobulins in children with demyelinating disorders or neurologic paraneoplasmatic syndromes were found.

Conclusion: In this review, we summarize the recent advances in the field of intravenous immunoglobulins used in pediatric neurological diseases. Literature data supports a beneficial effect in this age group. Whilst awaiting the results of large scale studies, administration of intravenous immunoglobulins could be justified in refractory child epilepsy. Otherwise, its use should be guided by the individual needs of each child, depending on the underlying neurological disease.

Cite this article as:

Gogou Maria , Papadopoulou-Alataki Efimia , Spilioti Martha , Alataki Sofia and Evangeliou Athanasios*, Clinical Applications of Intravenous Immunoglobulins in Child Neurology, Current Pharmaceutical Biotechnology 2017; 18 (8) . https://dx.doi.org/10.2174/1389201018666170915123700